Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bay State Times.
Press releases published on May 14, 2025
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
GlobeNewswire
·
May 14, 2025
Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional …
Desk-Based Roles See Application Surges Amid Slowing Demand, Growing AI Adoption, While Frontline and Hourly Workforce Face Talent Shortages
GlobeNewswire
·
May 14, 2025
DENVER, May 14, 2025 (GLOBE NEWSWIRE) -- As economic conditions shift across industries, the U.S. job market is showing clear signs of fragmentation. According to the new Job Seeker Nation report from Employ, desk-based job sectors are experiencing a …
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
GlobeNewswire
·
May 14, 2025
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary …
Powerdyne International Inc. Announces A letter to the Shareholders update
GlobeNewswire
·
May 14, 2025
North Reading, MA, May 14, 2025 (GLOBE NEWSWIRE) -- Powerdyne International, Inc. (Ticker: PWDY) ("Powerdyne" and / or the “Company”) announces A Letter to the Shareholders Update. Dear Shareholders, We would like to thank all our shareholders for their …
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 -- -- Cash resources of $42.2 million as of March 31, 2025, expected to fund operations into 1Q 2026 -- …
3Daughters Selects Connect Labs by Wexford - Baltimore for New Corporate Headquarters
GlobeNewswire
·
May 14, 2025
Access to Wexford Knowledge Community Platform Supports Creation of a Women’s Health Science Hub Presence within UMB BioPark Ecosystem and Provides Critical Connections for Growth BALTIMORE, May 14, 2025 (GLOBE NEWSWIRE) -- 3Daughters, Inc., a clinical …
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
GlobeNewswire
·
May 14, 2025
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology ( …
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive …
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 14, 2025
- Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first …
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
May 14, 2025
Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- …
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy
GlobeNewswire
·
May 14, 2025
WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has submitted a Citizen Petition with the U.S. Food and Drug Administration (FDA) calling on the Agency to evolve from historical approaches to the development …
Mercury Introduces First Safety-Certifiable, SOSA-aligned Mission Computer for Aviation Platforms
GlobeNewswire
·
May 14, 2025
ANDOVER, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a technology company that delivers mission-critical processing power to the edge, today introduced the first safety-certifiable, SOSA-aligned aviation …
Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases
GlobeNewswire
·
May 14, 2025
Tisento to Present at the “Primary Mitochondrial Diseases” Therapeutic Development Workshop Hosted by the Reagan-Udall Foundation for the FDA on May 22, 2025 Tisento to Sponsor the First Externally Led Patient-Focused Drug Development Meeting Dedicated to …
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
GlobeNewswire
·
May 14, 2025
FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with …
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor …
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed after a single infusion of VERVE- …